Thank you, Chair.
We had been waiting for a costing study for a good while. Obviously, it's great to have data at hand when making decisions.
Given the results that you have presented, which include possible cost reductions, my first reaction is to say that clearly, we can make improvements here.
In your study, you used the list of drugs covered by the Régie de l'assurance-maladie du Québec, the RAMQ. Are you able to say if the results could apply elsewhere, using Quebec as an example? Would it be possible to reduce current costs in each and every province using the comparison model that you have in your study, without creating a pan-Canadian pharmacare plan per se?
Have I expressed myself clearly?